Legend:
CC = Baltimore Convention Center,
H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
|
620 * !
|
Thu, 8/3/2017,
8:30 AM -
10:20 AM
|
CC-343
|
Dose-Finding for Monotherapy and Combination Therapy in Oncology and Other Complex Studies — Contributed Papers
|
Biopharmaceutical Section
|
Chair(s): Godwin Yung, Takeda Pharmaceutical
|
8:35 AM
|
Dose Selection in Phase 2 Studies for a Drug Combination Using a Response Surface Modeling Technique
—
Hongtao Zhang, AbbVie Inc. ; Jingjing Gao, AbbVie Inc. ; Qiming Liao, AbbVie Inc. ; Alan Hartford, AbbVie ; Jyotirmoy Dey, AbbVie Inc.
|
8:50 AM
|
Incorporating Pharmacokinetic Assessment in Bayesian Phase I Trial Design in Oncology Area
—
Kentaro Takeda, Astellas Pharma Global Development, Inc. ; Kanji Komatsu, Astellas Pharma Inc. ; Satoshi Morita, Kyoto University Graduate School of Medicine
|
9:05 AM
|
Impact of Mis-Specified Prior in Combination Dose Finding
—
Lixia Pei, Janssen Research & Development
|
9:20 AM
|
Design of Phase I/II Drug Combination Cancer Trials Using CRM and Adaptive Randomization
—
Mourad Tighiouart, Cedars-Sinai Medical Center ; Matthieu Clertant, Cedars-Sinai Medical Center
|
9:35 AM
|
A Personalized Bayesian Information-Driven Dose-Finding Design
—
Ilaria Domenicano, Dana-Farber Cancer Institute/University of Rome
|
9:50 AM
|
Multiplicity Adjustment in Two Dose-Response Study Examples
—
Li He, Merck Research Laboratories ; Joseph Heyse, Merck & Co., Inc.
|
10:05 AM
|
Continual Reassessment Method for Partially Ordered Groups
—
Bethany Horton, The University of Virginia ; Nolan Wages, The University of Virginia ; Mark Conaway, The University of Virginia
|